Skip navigation

Calls to Action

Cure Autism Now and Lipomics Collaborate on New Biomarker

Study
October 14, 2007


Cure Autism Now has partnered with Lipomics Technologies, a company that specializes in metabolite analysis and interpretation, for a new biomarker study of children with autism. This study may offer clues about the causes of autism and may lead to better therapies for autism and other neurodevelopmental disorders.

Results from preliminary research indicate a decrease in levels of an omega-3 fatty acid--docosahexaenoic acid, or DHA--in plasma of autistic individuals, confirming previous findings. In this new study, Lipomics will explore more extensive lipid profiling to see whether metabolic signatures of the disorder, such as DHA levels, are present in male children with autism, as compared with their typical male siblings and unrelated typical children in the same age group.

Lipomics will analyze DNA samples collected by the Autism Genetic Resource Exchange (AGRE) to generate lipomic profiles for each of the samples using its TrueMass lipid analysis. This service can measure the levels of hundreds of lipid metabolites from each small sample.

"Deficiencies of lipid metabolism could be related to some of the physiological symptoms found in autism," said Clara Lajonchere, Ph.D., AGRE Program Director. "The data generated by Lipomics will contribute important new biological information to the growing body of research available to scientists worldwide through AGRE. The results may offer promising clues to understanding the causes of autism. Cure Autism Now hopes to replicate and extend its initial findings by using the expertise that Lipomics provides."
"We are pleased to be working with Cure Autism Now and its AGRE resource to profile the metabolic signatures of autism that we hope will lead to new, more effective therapeutics that can be used in the treatment of this rapidly increasing disorder," said Dr. Tom Anderson, president and CEO of Lipomics Technologies.

About Cure Autism Now
Cure Autism Now is a non-profit organization dedicated to promoting and funding autism research and accelerating the pace of scientific progress toward effective treatments and a cure for autism. The organization is the leading funder of biological research in autism, providing more than $20 million for research grants, education, outreach and scientific resources, including the establishment and ongoing support of the Autism Genetic Resource Exchange (AGRE). Cure Autism Now has chapters in Los Angeles, Orange County and San Francisco, California; New Jersey, New York City, Chicago, Philadelphia, Houston, Seattle, Maryland/DC Area, and Honolulu. For more information about Cure Autism Now, go to
http://www.cureautismnow.org

About Lipomics Technologies, Inc.
Lipomics develops tools for drug discovery and personalized medicine using proprietary technologies for lipid metabolism analysis and data interpretation. We generate a comprehensive understanding of lipid metabolism from plasma, serum or tissue samples by combining quantitative measurements of lipid metabolites with proprietary algorithms for mapping the lipomic profiles to biochemical pathways. In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technology to speed drug discovery processes, improve clinical trial stratification, reduce late-stage drug attrition, discover new biomarkers and develop early tests for monitoring drug response. More information about Lipomics can be found at www.lipomics.com. TrueMass and the Lipomics logo are registered U.S. trademarks and/or service marks of Lipomics Technologies, Inc.